Why does CMA hyperactivation occur broadly across cancers despite tissue-specific contexts?

OPEN

The abstract notes CMA dysregulation is 'increasingly recognized in various cancers' but states mechanisms remain unclear. This suggests a fundamental gap in understanding whether CMA hyperactivation represents a universal cancer hallmark or distinct tissue-specific processes. Gap type: open_question Source paper: Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity. (2026, Nature communications, PMID:41390755)

Priority: 0.75 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Why does CMA hyperactivation occur broadly across cancers despite tissue-specific contexts? is a 0.75 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Why does CMA hyperactivation occur broadly across cancers despite tissue-specific contexts? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (1)

HSP70CMA

biomarker for (1)

LAMP2ACMA

is upregulated to remove (1)

35000546CMA

regulates (1)

CMAROS
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps